Navigating the AI regulatory maze: Why 91% of life sciences professionals feel lost
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your…
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your…
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in…
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in…
The evolution of pharmaceutical manufacturing is driven largely by the rising demands facing the industry. Inflation, strict regulations and a…
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially…
The global cell and gene therapy (CGT) market is expanding at a rapid rate, and will be worth $76bn by…
With the MS Trust estimating that more than 2.9 million people worldwide have multiple sclerosis (MS), new therapies are urgently…
Maintaining efficiency across the supply chain is essential to ensure potentially life-saving pharmaceutical products reach the patients who need them.…
Oligonucleotides (oligos) are short strands of synthetic DNA or RNA that offer huge potential in treatments for a wide range…
Every stage of the pharmaceutical supply chain is critical if life-saving drugs are to make it to market – and…